Abstract
Background Wheeze in the preschool age has a high prevalence and healthcare burden. There is conflicting evidence of the effectiveness of montelukast, a leukotriene receptor antagonist, in preschool wheeze. Recent meta-analyses have focused on its use in viral induced or multiple-trigger wheeze, however such groups are unlikely to exist in real-life and change with time, recently highlighted in an international consensus report. We have therefore sought to investigate the effectiveness of montelukast in all children with preschool wheeze. Methods The PubMed, Cochrane Library, Ovid Medline and Ovid EMBASE were screened for randomised controlled trials (RCTs), examining the efficacy of montelukast compared with placebo in children with the preschool wheeze. Results Five trials containing 3960 patients (6 months to 5 years) with a preschool wheezing disorder were analysed. Meta-analyses of studies of intermittent montelukast, showed no benefit in preventing episodes of wheeze (Mean Difference (MD) 0.07, 95% CI -0.14 to 0.29), reducing unscheduled medical attendances (MD -0.13, 95% CI -0.33 to 0.07) and reducing oral corticosteroid use (MD -0.06, 95% CI -0.16 to 0.02). The pooled results of the continuous regimen showed no significant difference in the number of wheezing episodes between the montelukast and placebo groups (MD -0.40, 95% CI -1.00 to 0.19). Discussion This review highlights that the currently available evidence do not support the routine use of montelukast in children with preschool wheeze. We recommend further studies to investigate if the specific 9montelukast responder9 phenotype exists, and how these can be easily identified in the clinical setting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.